Olanzapina w formie tabletek rozpuszczających się w ustach Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2013
Słowa kluczowe:
olanzapina rozpuszczalna, tabletki rozpuszczające się w ustach
##plugins.themes.bootstrap3.article.main##
Abstrakt
Olanzapina w formie tabletek rozpuszczających się w ustach (ODT) ma takie same właściwości farmakologiczne jak olanzapina w standardowych tabletkach, lecz szybciej ulega absorpcji i wcześniej jest wykrywana w osoczu. Dlatego jest ona odpowiednia do leczenia schizofrenii w ostrej fazie i może być podawana zamiast zastrzyków. Forma ODT jest przydatna, gdy pacjent ma trudności z połykaniem lub trawieniem. Olanzapina ODT zapewnia lepszą współpracę z pacjentem niż olanzapina w formie standardowej, a także ma korzystniejszy profil metaboliczny.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. McLaughlin R, Banbury S, Crowley K. Orally disintegrating tablets. The effect of recent FDA guidance on ODT technologies and applications. Pharmaceutical Technology 2009; IX (supplement).
2. Hori H, Ueda N, Yoshimura R et al. Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study. World J Biol Psychiatry 2009; 10(4): 741-745.
3. Bergstrom RF, Mitchell M, Witcher J et al. Rapid onset of absorption with olanzapine orally disintegrating tablets. Schizophrenia Research 2004; 67 (supl. 1): 160.
4. Karagianis J, Hoffmann VP, Arranz B et al. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Human Psychopharmacology 2008; 23: 275-281.
5. Czekalla J, Wagner T, Schacht A et al. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Preferences and Adherence 2007; 1: 19-27.
6. Dardennes R, Chartier F, Heurtebize N et al. Naturalistic use of the orally disintegrating tablet formulation of olanzapine in acute schizophrenic patients: An observational prospective study. Int J Neuropsychopharmacol 2004; 7(supl. 2): P01.389.
7. Arranz B, San L, Duenas RM et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Human Psychopharmacology 2007; 22: 11-15.
8. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
9. Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008; 371: 1085-1097.
10. Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087.
11. Karagianis J, Novick D, Pecenak J et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009; 63: 1578-1588.
12. FDA, Food and Drug Administration.
13. Leucht S, Corves C, Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31-41.
14. Leucht S, Komossa K, Rummel-Kluge C et al. A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. Am J Psychiatry 2009; 166: 152-163.
15. Tiihonen J, Lönnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374(9690): 620-627.
16. De Haan L, Van Amelsvoort T, Rosien K et al. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004; 175: 389-390.
17. Basson BR, Kinon BJ, Taylor CC et al. Factors influencing acute weight gain in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry 2001; 62: 231-238.
18. Zipursky RB, Gu H, Green AI et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187: 537-543.
19. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systemic review and meta-analysis. Neuropsychopharmacology 2010; 35: 1520-1530.
20. Chawla B, Luxton-Andrew H. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Human Psychopharmacology 2008; 23: 211-216.
21. Crocq MA, Guillon MS, Bailey PE et al. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. European Psychiatry 2007; 22: 453-454.
22. Łoza B, Grzesiewska J, Wójcik M. Przypadek wczesnej schizofrenii leczonej w warunkach politerapii olanzapiną i ziprasidonem. Neuropsychiatria. Przegląd Kliniczny 2009; 1(1): 38-40.
23. San L, Casillas M, Ciudad A et al. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neuroscience & Therapeutics 2008; 14: 208-214.
24. Ciorabai EM, Oyffe I, Dilbaz N et al. Patients preference of olanzapine orodispersible tablet compared with olanzapine classic oral tablet in a multinational, randomized, crossover study. European Psychiatry 2008; 23(supl. 2): 150-151.
25. Kraemer S, Chartier F, Augendre-Ferrante B et al. Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study. Hum Psychopharmacol 2012; 27(3): 284-294.
26. Ascher-Svanum H, Furiak NM, Lawson AH et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Economics 2012; 15(3): 531-547.
2. Hori H, Ueda N, Yoshimura R et al. Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study. World J Biol Psychiatry 2009; 10(4): 741-745.
3. Bergstrom RF, Mitchell M, Witcher J et al. Rapid onset of absorption with olanzapine orally disintegrating tablets. Schizophrenia Research 2004; 67 (supl. 1): 160.
4. Karagianis J, Hoffmann VP, Arranz B et al. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Human Psychopharmacology 2008; 23: 275-281.
5. Czekalla J, Wagner T, Schacht A et al. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Preferences and Adherence 2007; 1: 19-27.
6. Dardennes R, Chartier F, Heurtebize N et al. Naturalistic use of the orally disintegrating tablet formulation of olanzapine in acute schizophrenic patients: An observational prospective study. Int J Neuropsychopharmacol 2004; 7(supl. 2): P01.389.
7. Arranz B, San L, Duenas RM et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Human Psychopharmacology 2007; 22: 11-15.
8. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
9. Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008; 371: 1085-1097.
10. Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087.
11. Karagianis J, Novick D, Pecenak J et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009; 63: 1578-1588.
12. FDA, Food and Drug Administration.
13. Leucht S, Corves C, Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31-41.
14. Leucht S, Komossa K, Rummel-Kluge C et al. A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. Am J Psychiatry 2009; 166: 152-163.
15. Tiihonen J, Lönnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374(9690): 620-627.
16. De Haan L, Van Amelsvoort T, Rosien K et al. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004; 175: 389-390.
17. Basson BR, Kinon BJ, Taylor CC et al. Factors influencing acute weight gain in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry 2001; 62: 231-238.
18. Zipursky RB, Gu H, Green AI et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187: 537-543.
19. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systemic review and meta-analysis. Neuropsychopharmacology 2010; 35: 1520-1530.
20. Chawla B, Luxton-Andrew H. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Human Psychopharmacology 2008; 23: 211-216.
21. Crocq MA, Guillon MS, Bailey PE et al. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. European Psychiatry 2007; 22: 453-454.
22. Łoza B, Grzesiewska J, Wójcik M. Przypadek wczesnej schizofrenii leczonej w warunkach politerapii olanzapiną i ziprasidonem. Neuropsychiatria. Przegląd Kliniczny 2009; 1(1): 38-40.
23. San L, Casillas M, Ciudad A et al. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neuroscience & Therapeutics 2008; 14: 208-214.
24. Ciorabai EM, Oyffe I, Dilbaz N et al. Patients preference of olanzapine orodispersible tablet compared with olanzapine classic oral tablet in a multinational, randomized, crossover study. European Psychiatry 2008; 23(supl. 2): 150-151.
25. Kraemer S, Chartier F, Augendre-Ferrante B et al. Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study. Hum Psychopharmacol 2012; 27(3): 284-294.
26. Ascher-Svanum H, Furiak NM, Lawson AH et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Economics 2012; 15(3): 531-547.